SynthesisANZ journal of surgery2026
Oncovascular Resection in Pelvic Exenteration: A Systematic Review.
Synthesis in ANZ journal of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundResection of major vascular structures may be required to achieve R0 resection in pelvic exenteration surgery for advanced pelvic malignancy. The evidence base for pelvic oncovascular techniques is limited, with patient outcomes following these procedures not widely reported.
objectivesThis systematic review synthesises the current literature on R0 resection and 30-day mortality rates following oncovascular pelvic exenteration.
methodsA systematic review was conducted according to a pre-defined protocol (PROSPERO ID CRD42024613055). MEDLINE, EMBASE, Cochrane Library and Web of Science were interrogated between January 1, 1947, to July 1, 2025. Studies exploring oncovascular resection in advanced pelvic malignancy were considered. Pre-1980 studies were included narratively but excluded from quantitative synthesis. Data were extracted on R0 resection, postoperative morbidity and mortality. The ROBINS-1 V2 tool was used to assess bias.
resultsSeventeen studies met the inclusion criteria. After excluding three pre-1980 studies, 411 contemporary patients were included in quantitative analysis. Among curative-intent procedures (n = 334), the R0 resection rate was 65.3% (218/334). With regards to morbidity, Clavien-Dindo grade I-II complications occurred in 56.9% (227/399) and grade III-IV complications in 28.5% (109/382). Thirty-day mortality was 1.9% (8/411). Median overall survival was 41 months (range 34-57.6), with median disease-free survival of 27 months (range 8-43.2).
conclusionApproximately two thirds of patients undergoing oncovascular pelvic exenteration achieved R0 resection, with morbidity and 30-day mortality of 1.9%. Outcomes remain inferior to contemporary benchmark series for conventional exenteration, reflecting the pioneering phase of oncovascular practice. Centralisation, rigorous audit and benchmarking and improved patient selection should be the focus of future work to improve R0 and complication rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.